BioSpace News Archive

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection program

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device.

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET.

CDMO with a Six Decades-Long Reputation for Quality and Service Doubles Its Capacity to Take on New Development Projects

-- Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease -- Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi® -- Approximately $72.2 Million in Cash and Cash Equivalents at December 31, 2020

Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 25, 2021, to provide a corporate update and discuss details of the Company’s financial results for the quarter and year ended December 31, 2020

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after U.S. financial markets close. Management will host a conference call on Wednesday, February 24, 2021, at 4:30 p.m. ET to provide a general business update and to discuss fourth quarter and full year 2020 financial results.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical study of VAL-083